Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 7 examiners • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Arcutis Biotherapeutics Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 7 distinct examiners and 5 distinct art units, showing meaningful distribution with repeated assignments at both levels.
SOROUSH, LAYLA is the busiest examiner, with 3 pending matters. That examiner represents the clearest concentration point, while the remaining matters require coordination across the other examination assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 6 (67%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 3 | 40.5% | +43.4% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 28d overdue |
| 18984051 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | GEMBEH, SHIRLEY V | — |
| 18962371 | STABLE FORMULATIONS OF SHR0302 | BRAUN, MADELINE E | — |
| 18942389 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | ISMAIL, REHANA | — |
| 18827222 | DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS | SOROUSH, LAYLA | — |
| 18795580 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18789083 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | — |
| 18627861 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 4 |
| 1624 | 1 |
| 1625 | 1 |
| 1611 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18984051 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | GEMBEH, SHIRLEY V | — | Other | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18962371 | STABLE FORMULATIONS OF SHR0302 | BRAUN, MADELINE E | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18942389 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | ISMAIL, REHANA | 1625 | DP | Non-Final OA | — | Pending | Nov 09, 2024 |
| 18827222 | DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | — | Pending | Sep 06, 2024 |
| 18795580 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103DP | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18789083 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | 1622 | §102§103DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18627861 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | 1622 | §102§103DP | Final Rejection | — | Pending | Apr 05, 2024 |
| 18037316 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | JOSEPH, JANET | 1611 | §102§103DP | Non-Final OA | — | Pending | May 16, 2023 |
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 1612 | §103 | Final Rejection | 28d overdue | Pending | Dec 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArcutis Biotherapeutics Inc. has 9 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Layla Soroush has the most, with 3 of Arcutis Biotherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
